569 related articles for article (PubMed ID: 17586092)
1. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin--a targeted chemotherapy?
von Mehren M
Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
[No Abstract] [Full Text] [Related]
4. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
Grosso F; Sanfilippo R; Virdis E; Piovesan C; Collini P; Dileo P; Morosi C; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Aug; 20(8):1439-44. PubMed ID: 19465423
[TBL] [Abstract][Full Text] [Related]
7. Complete response of a recurrent-metastatic liposarcoma with dedifferentiated histological features following the administration of trabectedin and review of literature.
Kus T; Aktas G; Kalender ME; Tutar E; Ulker E; Camci C
J Cancer Res Ther; 2015; 11(4):974-6. PubMed ID: 26881560
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
Gronchi A; Bui BN; Bonvalot S; Pilotti S; Ferrari S; Hohenberger P; Hohl RJ; Demetri GD; Le Cesne A; Lardelli P; Pérez I; Nieto A; Tercero JC; Alfaro V; Tamborini E; Blay JY
Ann Oncol; 2012 Mar; 23(3):771-776. PubMed ID: 21642514
[TBL] [Abstract][Full Text] [Related]
9. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
10. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
[TBL] [Abstract][Full Text] [Related]
11. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma.
Morioka H; Takahashi S; Araki N; Sugiura H; Ueda T; Takahashi M; Yonemoto T; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Susa M; Nakayama R; Nishimoto K; Kikuta K; Horiuchi K; Kawai A
BMC Cancer; 2016 Jul; 16():479. PubMed ID: 27418251
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
13. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J;
Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M; Badri N; Galmarini CM; Allavena P
Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
[TBL] [Abstract][Full Text] [Related]
19. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]